Lung Cancer
By Chase Doyle
Frank Sierawski had never smoked and had no family or personal history of lung problems, but what started out as a distressing cough ended up being lung cancer. Read More ›
Oncology nutritionist Julie Lanford presents nutrition tips for patients with lung cancer, advocating for a health plan to combat unintentional weight loss and managing poor appetite. Read More ›
When her mother was diagnosed with stage IIIB lung cancer, Danielle Hicks took an active role in caring for her and found her purpose helping other patients going through the same fight. Read More ›
In September 2020, the FDA approved a second drug for the treatment of patients with lung cancer and RET fusions, improving the treatment options available today for patients with this type of lung cancer. Read More ›
By A. J. Patel
A.J. Patel, who ran around 20 miles a week as a semi-professional soccer referee, was shocked to get a lung cancer diagnosis and dismayed when his relationships strained. Then, an estranged uncle came to his aid. Read More ›
By Dana Taylor
At the October 2020 conference of the European Society for Medical Oncology (ESMO), researchers presented information on new or recently approved targeted therapies and immunotherapies for lung cancer. Read More ›
In May 2020, the FDA approved the first drug ever for the treatment of patients with lung cancer and RET fusions, a type of biomarker that can lead to lung cancer and requires specific drug therapy. Read More ›
By Chase Doyle
One biomarker that is involved in lung cancer is the ALK mutations. Although several drugs are now available for this type of lung cancer, new evidence shows that some patients may need different therapies. Read More ›
By Phoebe Starr
Patients with extensive-stage small-cell lung cancer, a rare type of lung cancer, now have a new first-line treatment option with Imfinzi (durvalumab), a PD-L1 inhibitor, in combination with chemotherapy, according to new results presented at the 2020 ASCO annual meeting. This new combination has been shown to improve survival for these patients, who do not have many treatment options and whose prognosis (survival outlook) is less than 5 years. Read More ›
Patients with metastatic (spreading to other parts of the body) non–small-cell lung cancer who received the drug Tecentriq (atezolizumab) as a first-line therapy had improvements in physical functioning, without worsening of their lung cancer–related symptoms, compared with patients who received chemotherapy. Read More ›